Layout 1 OZOILE®: evaluating its impact and future applications in inflammatory dermatological treatments Eur J Transl Myol 35 (1) 13071, 2025 doi: 10.4081/ejtm.2024.13071 Dear Editor, I would like to express my sincere appreciation for the publication and detailed discussion of therapies for der- matological and inflammatory conditions, as exemplified in the recent article “Onychocryptosis: a retrospective study of clinical aspects, inflammation treatment, and pain management using Ozoile as a hydrogel and cream for- mulation” by Vincenzo Francavilla et al. This insightful study has provided a comprehensive overview of the man- agement of onychocryptosis, a common and often distres- sing condition, and has highlighted the innovative use of OZOILE® in a clinical setting.1 Ingrown toenails, also known as onychocryptosis, frequently cause significant pain and can severely impact the quality of life. Traditional treatment approaches often involve invasive procedures and can carry risks of com- plications. The introduction of OZOILE® as a therapeutic option represents a promising alternative. OZOILE® has demonstrated notable efficacy due to its proven antibac- terial, antifungal, and anti-inflammatory properties. These qualities not only enhance patient comfort but also facili- tate a faster recovery, minimizing pain and reducing the risk of adverse outcomes associated with conventional treatments. Our own study have further supported the effectiveness of OZOILE® by showing its ability to lower crucial in- flammatory markers such as IL-1β, TNF-α, and IFN-γ. This anti-inflammatory effect is significant because it con- tributes to improved tissue integrity and effective stimu- lation of the tissue repair process. By reducing inflammation and promoting healing, OZOILE® offers a substantial advantage over traditional treatments that may not address the underlying inflammatory mechanisms as effectively.2 Moreover, OZOILE® has shown particular promise in treating Lichen Sclerosus (LS), a chronic inflammatory condition affecting the glans, penis, and foreskin, in pedi- atric patients. This condition is notoriously challenging to manage, and current treatment options often fall short in providing relief. The application of OZOILE® has yielded encouraging results in reducing symptoms and managing the disease. Studies have revealed that OZOILE® can ef- fectively lower inflammatory markers associated with BXO, thus improving tissue integrity and aiding in the re- pair of damaged tissue. Positive indicators such as in- creased E-cadherin expression and decreased TG2 levels further substantiate the efficacy of ozone therapy in con- trolling inflammation and supporting tissue regeneration.3 The potential of OZOILE® extends beyond these specific conditions, suggesting that its benefits could be harnessed in other therapeutic contexts as well. The integration of OZOILE® into therapeutic protocols for conditions such as ingrown toenails and BXO could significantly enhance clinical outcomes and reduce complications associated with traditional treatments.4 However, it is crucial that further large-scale randomized clinical trials are con- ducted to confirm the efficacy and safety of OZOILE® in these and other contexts. Finally, we would like to congratulate Vincenzo Franca- villa et al. for their insightful and forward-thinking work on this emerging and complex area of dermatological treatment. Their findings provide valuable guidance for clinical practice and highlight the importance of con- tinued exploration of OZOILE®’s broader applications in various medical fields. As research progresses, it will be crucial to evaluate how OZOILE® can be effectively utilized in different therapeutic scenarios and whether it can be integrated into existing treatment protocols to en- hance patient outcomes. Their commitment to focusing on a potentially transformative therapy is commendable, and their study offers useful insights for managing com- plex conditions such as ingrown toenails and balanitis xerotica obliterans, the latter of which has also been pre- viously studied by us. In conclusion, while the preliminary results are promis- ing, ongoing research and clinical trials are essential to fully understand the potential of OZOILE® and its Key Words: Ozoile; lichen sclerosus; dermatological lesions; olive oil ozonide. Eur J Transl Myol 35 (1) 13071, 2025 doi: 10.4081/ejtm.2024.13071 OZOILE®: evaluating its impact and future applications in inflammatory dermatological treatments Fabiola Cassaro,1 Deborah Basilotta,1 Monica Currò,2 Pietro Impellizzeri,1 Carmelo Romeo,1 Salvatore Arena1 1Unit of Pediatric Surgery, Department of Human Pathology of Adult and Childhood “Gaetano Barresi”, University of Messina, Italy; 2Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Italy. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. - 20 - OZOILE®: evaluating its impact and future applications in inflammatory dermatological treatments Eur J Transl Myol 35 (1) 13071, 2025 doi: 10.4081/ejtm.2024.13071 broader implications for medical practice. By advancing our knowledge and exploring new applications, we can unlock the full potential of this innovative therapy and enhance the quality of care for patients across a wide range of conditions. Conflicts of interest The authors declare no conflict of interest. Ethics approval Not applicable. Availability of data and materials All data generated or analyzed during this study are in- cluded in this published article. Corresponding author Salvatore Arena, Unit of Pediatric Surgery, Department of Human Pathology of Adult and Childhood “Gaetano Bar- resi”, University of Messina, 98121 Messina, Italy. ORCID ID: 0000-0003-0276-9211 E-mail: salarena@unime.it Co authors Fabiola Cassaro ORCID ID: 0000-0002-1244-8414 E-mail: fabiola.cassaro@studenti.unime.it Deborah Basilotta ORCID ID: 0009-0008-8775-584X E-mail: deborah.basilotta@studenti.unime.it Monica Currò ORCID ID: 0000-0001-8852-7023 E-mail: monica.curro@unime.it Pietro Impellizzeri ORCID ID: 0000-0003-4262-2433 E-mail: impellizzerip@unime.it Carmelo Romeo ORCID ID: 0000-0002-7616-5480 E-mail: romeoc@unime.it References 1. Francavilla V, Secolo G, D’Armetta M, et al. Onycho- cryptosis: a retrospective study of clinical aspects, in- flammation treatment and pain management using Ozoile as a hydrogel and cream formulation. Eur J Transl Myol 2024;34:12487. 2. Currò M, Russo T, Ferlazzo N, et al. Anti-inflam- matory and tissue regenerative effects of topical treat- ment with ozonated olive oil/vitamin E acetate in balanitis xerotica obliterans. Molecules 2018;23:645. 3. Bertuccio MP, Rizzo V, Arena S, et al. Ozoile reduces the LPS-induced inflammatory response in colonic epithelial cells and THP-1 monocytes. Curr Issues Mol Biol 2023;45:1333-48. 4. Russo T, Currò M, Ferlazzo N, et al. Stable ozonides with vitamin E acetate versus corticosteroid in the treatment of lichen sclerosus in foreskin: evaluation of effects on inflammation. Urol Int 2019;103:459-65. Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their af- filiated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. Submitted: 9 September 2024. Accepted: 3 October 2024. Early access: 3 December 2024. - 21 - mailto:salarena@unime.it mailto:fabiola.cassaro@studenti.unime.it mailto:deborah.basilotta@studenti.unime.it https://orcid.org/0000-0001-8852-7023 mailto:0000-0003-4262-2433 mailto:impellizzerip@unime.it